About This Provider

WHAT IS OZEMPIC® (SEMAGLUTIDE)?

Ozempic® (semaglutide) is a once-weekly injectable GLP-1 RA—a class of medicines more formally known as glucagon-like peptide-1 receptor agonists. It is one of the medications prescribed by Calibrate doctors (when clinically appropriate) for the treatment of obesity, working in conjunction with the Calibrate Metabolic Reset.

Ozempic® is manufactured by Novo Nordisk, a pharmaceutical company based in Denmark that also manufactures Wegovy®. It has been FDA-approved since 2017.

Both Ozempic® and Wegovy® contain the same active ingredient. Wegovy® provides a dose that titrates up to 2.4 mg of semaglutide, whereas Ozempic® dosing is available in a maximum of 2.0 mg of semaglutide. Learn more about the new 2.0 mg dose here.

While Ozempic® is currently FDA-approved for use in patients with type-2 diabetes, clinical studies show that its active ingredient, semaglutide, is safe and effective in treating overweight or obesity. Just as it does in adults with type-2 diabetes, Ozempic® can improve blood sugar levels in adults with insulin resistance or prediabetes—and is an effective tool for weight loss among both groups.

How much weight can you lose with Ozempic®? According to Novo Nordisk, a one-year study found that adults with an average starting weight of 197 pounds lost around:

- 4.6% of their body weight on 0.5 mg Ozempic®

- 6.1% of their body weight on 1 mg Ozempic®

Ozempic® is prescribed by Calibrate doctors

Ozempic® is one of the medications prescribed by Calibrate doctors, if clinically appropriate, to work in conjunction with the Calibrate Metabolic Reset. Our program combines 1:1 video coaching, medication, and lifestyle changes for 10%+ weight loss or your money back (see terms).

Successful and sustained weight loss with Ozempic® requires more than just the injection of the drug itself—it also involves intensive lifestyle interventions, many of which are difficult to manage alone.

With Calibrate, members benefit from comprehensive, one-on-one support that spans four key areas: Food intake, exercise, sleep, and emotional health.

The Semaglutide Research directory

Industry Leading Providers

Explore Our Directory

Semaglutide Research

13894 South Bangerter Parkway
Draper, Utah 84020
United States of America